Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses

Withdrawn before enrolling · Phase 2/Phase 3 · Has a placebo group

Conditions studied: Precancerous Condition

In brief

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of celecoxib may be an effective way to prevent actinic keratoses. PURPOSE: Randomized phase II/III trial to determine the effectiveness of celecoxib in preventing skin cancer in patients who have actinic keratoses.

Key facts

Study ID

NCT00027976

Run by

University of Alabama at Birmingham

People needed

0

Starts

2001-12-01

Expected to finish

2005-12-01

Last updated by the study team

2013-08-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama, United States
• Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center — Irvine, California, United States
• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
• Siteman Cancer Center at Barnes-Jewish Hospital — St Louis, Missouri, United States
• James P. Wilmot Cancer Center at University of Rochester Medical Center — Rochester, New York, United States
• University of Texas - MD Anderson Cancer Center — Houston, Texas, United States
• University of Wisconsin Comprehensive Cancer Center — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.